We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Treating PCOS With Semaglutide vs Active Lifestyle Intervention (TEAL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03919929
Recruitment Status : Recruiting
First Posted : April 18, 2019
Last Update Posted : August 11, 2022
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
University of Colorado, Denver

Brief Summary:
Girls with obesity and polycystic ovarian syndrome will receive either glucagon like peptide-1 receptor agonist therapy or a dietary intervention for 12 weeks to decrease the metabolic syndrome, in particular to lower hepatic fat and improve insulin sensitivity.

Condition or disease Intervention/treatment Phase
PCOS Adolescent Obesity NAFLD Drug: Semaglutide 3mg and 7mg [Rybelsus] Other: Weight loss diet Phase 2 Phase 3

Detailed Description:
In obese girls with polycystic ovarian syndrome, testosterone and obesity combine to create unique pathology to increase metabolic disease including fatty liver and insulin resistance, which may be mediated by altered glucagon like peptide-1 activity. The investigators will treat girls with obesity and polycystic ovarian syndrome for 4 months with a glucagon like peptide-1 receptor agonist compared to dietary intervention to primarily lower hepatic fat and secondarily improve whole body and adipose insulin sensitivity. Mechanisms of hepatic metabolism, including rates of de novo lipogenesis and relative mitochondrial flux will also be assessed.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Treating PCOS With Semaglutide vs Active Lifestyle Intervention
Actual Study Start Date : May 3, 2019
Estimated Primary Completion Date : July 2024
Estimated Study Completion Date : July 2024

Resource links provided by the National Library of Medicine

Drug Information available for: Semaglutide

Arm Intervention/treatment
Active Comparator: Diet Intervention
Weight loss with dietary intervention
Other: Weight loss diet
Prescribed weight loss diet to match weight loss in Drug arm

Experimental: GLP-1 Intervention
Participants will take a daily oral tablet of semaglutide for 4 months.
Drug: Semaglutide 3mg and 7mg [Rybelsus]
Once daily oral tablet of semaglutide for 4 months
Other Name: GLP-1 receptor agonist

Primary Outcome Measures :
  1. Change in Hepatic Fat Fraction [ Time Frame: Baseline and 12 weeks ]
    Change from baseline in presence/severity of hepatic fat fraction will be measured with MRI, and calculated via the Dixon method as the proton density hepatic fat fraction, which ranges from 0-75%.

Secondary Outcome Measures :
  1. Change in Rate of De Novo Lipogenesis [ Time Frame: Baseline and 12 weeks ]
    Change from baseline of the rate of overnight de novo lipogenesis will be measured utilizing stable isotope methods with deuterated water, and expressed as the rate of newly synthesized lipids in the serum triglyceride fraction.

  2. Change in Whole Body Insulin Sensitivity [ Time Frame: Baseline and 12 weeks ]
    Participants will undergo a 75 gram oral glucose tolerance test, and the change from baseline in whole body insulin sensitivity will be expressed as Si, calculated via the oral minimal model.

  3. Change in Adipose Insulin Sensitivity [ Time Frame: Baseline and 12 weeks ]
    Change from baseline of adipose insulin sensitivity will be calculated as the percent suppression of free fatty acids, and the nadir of free fatty acids during the oral glucose tolerance test.

Other Outcome Measures:
  1. Evaluation of Mitochondrial function via change in ratios of direct to indirect hepatic carbon flux in newly synthesized triglycerides [ Time Frame: Baseline and 12 weeks ]
    OSTT with UC13 glycerol baseline and 12 weeks

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years to 21 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Sedentary- less than 2 hours of moderate (jogging, swimming etc) exercise a week.
  2. BMI equal or greater than the 90th percentile for age and gender
  3. PCOS per the most stringent NIH criteria adapted for adolescents (irregular menses >12 months post-menarche and clinical or biochemical hypertestosteronemia
  4. Participants cannot be on hormonal contraception, so participants should remain abstinent or use reliable non-hormonal contraception (e.g. copper IUD) for the entire study period. For participants who receive semaglutide, they should avoid pregnancy for at least 2 months after stopping medication to avoid fetal exposure to the medication.

Exclusion Criteria:

  1. Diagnosed with or have a family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Family history of medullary thyroid cancer or thyroid nodule palpated by endocrinologist at screening.
  2. Use of medications known to affect insulin sensitivity: metformin (cannot have been used in the 3 months prior to screening), oral glucocorticoids within 10 days, atypical antipsychotics, immunosuppressant agents, HIV medications, hormonal contraception (cannot have been used in the 6 months prior to screening). Dermal patch or vaginal ring contraception methods.Weight loss medications or stimulants. Use of other products containing other GLP-1 agonists.
  3. Currently pregnant or breastfeeding women. Development of pregnancy during the study period will necessitate withdrawal from the study.
  4. Severe illness requiring hospitalization within 60 days.
  5. Diabetes, defined as Hemoglobin A1C > 6.4%
  6. BMI percentile less than the 90th percentile for age and sex. Weight >325 lbs. or <84 lbs.
  7. Anemia, defined as Hemoglobin < 11 mg/dL
  8. Diagnosed major psychiatric or developmental disorder limiting informed consent.
  9. Implanted metal devices that are not compatible with MRI
  10. Use of blood pressure medications.
  11. Known liver disease other than NAFLD or AST or ALT >100 IU/L.
  12. Personal history of pancreatitis
  13. Known renal disease of any severity or an eGFR at screening of <45ml/min/1.73m2
  14. History of severe GI disease (e.g. gastroparesis)
  15. History of gallstones
  16. Untreated thyroid disease
  17. History of hypersensitivity to semaglutide
  18. Other causes of hyperandrogenism (example: tumor, CAH) or amenorrhea (untreated thyroid disease, tumor, primary ovarian failure, prolactinoma).
  19. Active symptoms or undergoing treatment for anorexia nervosa or binging/purging disorder

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03919929

Layout table for location contacts
Contact: Melanie Cree-Green, MD, PhD 720-777-5743 melanie.green@childrenscolorado.org
Contact: Yesenia Garcia-Reyes, MS 720-777-6984 yesenia.garciareyes@childrenscolorado.org

Layout table for location information
United States, Colorado
University of Colorado Anshutz Medical Campus/Children's Hospital Colorado Recruiting
Aurora, Colorado, United States, 80045
Contact: Yesenia Garcia Reyes    720-777-6984    yesenia.garciareyes@childrenscolorado.org   
Sponsors and Collaborators
University of Colorado, Denver
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Layout table for investigator information
Principal Investigator: Melanie Cree-Green, MD, PhD Children's Hospital Colorado
Layout table for additonal information
Responsible Party: University of Colorado, Denver
ClinicalTrials.gov Identifier: NCT03919929    
Other Study ID Numbers: 19-0636
1R01DK120612-01A1 ( U.S. NIH Grant/Contract )
First Posted: April 18, 2019    Key Record Dates
Last Update Posted: August 11, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Colorado, Denver:
Insulin Resistance
Additional relevant MeSH terms:
Layout table for MeSH terms
Pediatric Obesity
Nutrition Disorders
Body Weight